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Abstract—Inability to test at scale has become Achille’s heel in
humanity’s ongoing war against COVID-19 pandemic. An agile,
scalable and cost-effective testing, deployable at a global scale,
can act as a game changer in this war. To address this challenge,
building on the promising results of our prior work on cough-
based diagnosis of a motley of respiratory diseases, we develop an
Artificial Intelligence (AI)-based test for COVID-19 preliminary
diagnosis. The test is deployable at scale through a mobile app
named AI4COVID-19. The AI4COVID-19 app requires 2-second
cough recordings of the subject. By analyzing the cough samples
through an AI engine running in the cloud, the app returns
a preliminary diagnosis within a minute. Unfortunately, cough
is common symptom of over two dozen non-COVID-19 related
medical conditions. This makes the COVID-19 diagnosis from
cough alone an extremely challenging problem. We solve this
problem by developing a novel multi-pronged mediator centered
risk-averse AI architecture that minimizes misdiagnosis. At the
time of writing, our AI engine can distinguish between COVID-
19 patient coughs and several types of non-COVID-19 coughs
with over 90% accuracy. AI4COVID-19’s performance is likely
to improve as more and better data becomes available. This paper
presents a proof of concept to encourage controlled clinical trials
and serves as a call for labeled cough data. AI4COVID-19 is
not designed to compete with clinical testing. Instead, it offers
a complementing tele-testing tool deployable anytime, anywhere,
by anyone, so clinical-testing and treatment can be channeled to
those who need it the most, thereby saving more lives.
Index Terms—Artificial Intelligence, COVID-19, preliminary
medical diagnosis, pre-screening, public healthcare.
I. INTRODUCTION
By April 1, 2020 coronavirus disease 2019 (COVID-19)
has 823,626 confirmed cases, caused 40,598 deaths while
disrupting life in 206 countries and territories around the
world [1]. The losses are compounding everyday. Given no
vaccination or cure exists as of now, minimizing the spread by
timely testing the population and isolating the infected people
is the only effective defense mankind has at its disposal against
the unprecedentedly contagious COVID-19. However, ability
to deploy this defense strategy at this stage of pandemic hinges
on a nation’s ability to timely test significant fractions of its
population including those who are not contacting medical
system yet. Agile, scalable, and proactive testing capability
has emerged as the key differentiator in some nations’ ability
to cope and reverse the curve of the pandemic, and the lack
of the same is resulting in historic losses for others.
A. Why clinic visit based COVID-19 testing mechanisms alone
may not suffice to control the pandemic at this stage?
“Trace, Test and Treat” strategy succeeded in flattening the
pandemic curve (e.g., in South Korea, China, and Singapore)
at early stages of the spread. However, now in many parts
of the world the pandemic has already spread to an extent
that this strategy is not proving effective anymore [2]. Recent
studies show that, it is virus shedding often through coughing
by undiagnosed population that is contributing to much rapid
and covert spread [3]. Data shows that 81% of COVID-19
carriers do not develop symptoms too severe to seek medical
help and yet act as active spreaders [4]. Others develop
symptoms severe enough to prompt medical intervention only
after several days of being infected. These findings call for
a new strategy centered on “Pre-screen/test proactively at
population scale, self-isolate those tested positive for self-
healing without further spreading and channel medical care
towards the most vulnerable”.
As per World Health Organization (WHO) guidance,
Nucleic Acid Amplification Tests (NAAT) such as real-time
Reverse Transcription Polymerase Chain Reaction (rRT-PCR)
should be used for routine confirmation of COVID-19 cases by
detecting unique sequences of virus ribonucleic acid (RNA).
This test method while being the current gold standard is not
sufficing to control the pandemic for reasons that include but
are not limited to:
1) The geographical and temporal availability of such tests
is limited.
2) The clinical tests are too expensive and scarce to cover
the massive time-sensitive demand. Cost is not only an issue in
poor countries but even in rich countries like the USA where
26 million Americans remain uninsured.
3) This kind of test requires an in-person visit to a hospital,
clinic, lab or mobile lab. This inevitably requires breach of
isolation of the suspected patients. Such visit exposes more
members of the public to COVID-19 while the patient is en
route to the test facility. This is not a trivial problem given
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2the recent studies that show how highly stable and hence
contagious COVID-19 appears to be. For example, [5] shows
that the aerosol stability of COVID-19 is up to three hours in
aerosols and up to seven days on different surfaces.
4) Hospitals are already becoming over-crowded. Even if
the test is eventually done, while waiting for the medical staff
to take nasopharyngeal or oropharyngeal swab, the patient is
likely to expose many in the waiting rooms to the virus.
5) Turnaround time for current tests is several days, recently
stretching to 10 days in some countries as labs are becoming
overwhelmed [6], [7]. By the time a patient is diagnosed with
current methods, the virus has already been passed to many.
6) Even with social distancing in place, the presence of
untested carriers in the population exposes the first responders
to the infection because of the nature of their job. For
example, by the time of writing, hundreds of New York Police
Department members have been tested positive and 3 have lost
their lives [8].
7) In person testing methods put the medical staff, particu-
larly those with limited protection, at serious risk of infection.
This fact is becoming clear from the alarming number of
doctors and nurses being tested positive. For example, recent
reports show that thousands of healthcare workers around
the globe have been infected by COVID-19 [9]. This trend
is seriously concerning because medics are the first line
of defense in this war against pandemic. Their safety will
ultimately ensure a nation’s ability to safely navigate through
this pandemic. Inability to protect our medics can lead to
further shortage of medical care, and increased distress on
the already stressed medical staff. This in turn will deteriorate
the system’s ability to provide care to those most in need.
To make tests more readily accessible, on Mar. 28th the
United States Food and Drug Administration (FDA) has ap-
proved a faster test that can yield results in 15 minutes [10].
The test works similar to Polymerase Chain Reaction (PCR) by
identifying a portion of the COVID-19 RNA in the nasopha-
ryngeal or oropharyngeal swab. While a leap forward, this test
still requires an office visit and thus breach of social distancing
and self-isolation, i.e., though much faster, the newly approved
test still does not solve many of the aforementioned problems.
Furthermore, emerging reports of shortages of critical equip-
ment used to collect patient specimens, like masks and swabs,
could blunt its impact on controlling the pandemic [11], [12].
In last few weeks, two alternative approaches leveraging AI-
based analysis of the either X-ray [13] or CT Scan [14] images
have been proposed in literature. Thanks to recent advances
in AI-based image processing, these diagnosis approaches
offer very high accuracy, in some cases even better than the
rRT-PCR based test. However, both of these approaches while
bypassing the need for a radiologist to perform the diagnosis,
still require a visit to a well-equipped clinical facility. As a
result, these approaches also inherit the issues of office visit
based tests highlighted above.
It is mainly due to the difficulty of testing large swaths of
populations timely, safely and cost effectively and exactly track
the actual spread that even the richest nations on earth are
finding it difficult to contain the pandemic.
B. Proposed Cough Based COVID-19 Screening Approach
The idea of using cough for possible preliminary diagnosis
of COVID-19 and its feasibility is motivated by the following
key findings:
1) Our prior studies have shown that cough from distinct
respiratory syndromes have distinct latent features [15]. These
distinct features can be extracted by appropriate signal pro-
cessing and mathematical transformations of the cough sounds.
The features can then be used to train a sophisticated AI
engine for performing the preliminary diagnosis solely based
on cough. Our in-depth analysis of the pathomorphological
alternations caused by COVID-19 in the respiratory system
(reported in Section II), shows that the alternations are distinct
from those caused by other common non-COVID-19 respira-
tory diseases. This finding is corroborated by the meta-analysis
of several independent recent studies (reported in Section II)
that shows that COVID-19 infects the respiratory system in a
unique way. Therefore, it is logical to hypothesize that cough
caused by COVID-19 is also likely to have distinct latent
features. These distinct latent features can be exploited to train
a domain aware AI engine to differentiate COVID-19 caused
cough from non-COVID-19 cough. Our experiments (Figure 1,
Section III-C) show that this is indeed possible.
2) Cough is manifested as a symptom in majority (e.g.,
67.7% as per [16]), but not all COVID-19 carriers. However,
studies show that coughing is the main mechanism of social
spreading of COVID-19 [3]. Droplets containing virus emitted
through cough and landing on the surfaces where the virus
has been shown to survive for long periods of time, have been
reported to be the most prolific mechanism of spreading the
COVID-19 [17]. Hence, if a COVID-19 patient is not showing
cough as a symptom, that patient is most likely not spreading
as actively as a coughing COVID-19 patient. In other words,
cough-based testing, even if far from being as authentic as
clinical testing, can actually directly help in reducing R0 and
thus flattening the curve of the pandemic [4].
3) Due to the ease of measure, currently temperature scan
is the predominant screening method for COVID-19, e.g., used
at the airports. However, between cough and fever, the number
of non-COVID-19 medical conditions that can cause fever is
much larger than the non-COVID-19 conditions that can cause
cough. Our analysis shows that cough contains COVID-19
specific features even if it is non-spontaneous, i.e., when the
COVID-19 patient is asked to cough. This means cough can be
used as a pre-screening method by asking the suspect patient
to simulate cough, even if the patient is not showing it as a
spontaneous symptom.
C. Contributions and Paper Contents
The contributions and contents of this paper are outlined
below:
1) We analyze the pathomorphological changes caused by
the COVID-19 in the respiratory system from the studies ex-
amining X-rays and CT scans of live COVID-19 patients. Our
analysis also includes the autopsy report studies of deceased
patients. The purpose of this analysis is to apply first principle-
based approach. The goal is to see if the pathomorphological
3alterations caused by COVID-19 in the respiratory system (i.e.,
the part of body that produces cough sound) are different from
those caused by other common bacterial or viral infections.
This is to determine: is it even theoretically possible for
the COVID-19 cough to have any unique latent features.
The in-depth study of pertinent pathomorphological alterations
suggests that it is possible.
2) Building on the insights from first principle-based ap-
proach and our prior work that shows cough alone can be
used for successful AI based diagnosis of several respiratory
diseases [15], we hypothesize that “Cough sound can be
used at least for preliminary diagnosis of the COVID-19 by
performing differential analysis of its unique features relative
to other non-COVID-19 coughs”.
3) Continuing the medical literature review, we further
identify and shortlist the non-COVID-19 respiratory syn-
dromes that are relatively common and are known to cause
similar sounding cough as that of COVID-19 patients. The
shortlist includes pertussis, bronchitis, influenza, asthma,
pneumonia, bronchiolitis, and croup.
4) Given that even the shortlist is too long to gather reliable
data for this time sensitive project, we reduce the size of our
data gathering campaign to a manageable one by leveraging
the findings from literature which shows that cough caused by
the last five medical conditions in the shortlist above does have
features unique to each condition. Therefore, in the interest of
time, we go on to focus on the differential analysis of COVID-
19 cough, and coughs associated with pertussis and bronchitis
as these two conditions are not examined earlier.
5) We gather cough data of COVID-19, pertussis, and
bronchitis patients. Cough samples from COVID-19 patients
include both spontaneous cough (symptomatic) and non-
spontaneous (i.e., when the patient is asked to cough). This is
to make the test applicable to those who may not be showing
cough as a symptom yet but are already infected. We also
gather cough samples from otherwise healthy individuals with
no known medical condition, hereafter referred to as normal
cough. The normal cough is included in the analysis to see if
it can be differentiated from the simulated cough produced by
the COVID-19 patients. Using these data, we test the hypoth-
esis using a variety of data analysis and pre-processing tools.
Multiple alternative analysis approaches show that COVID-
19 associated cough does have unique features, at least when
compared to pertussis, bronchitis, and the normal cough.
6) Building on the insights from domain knowledge and
data, we develop an AI engine for preliminary diagnosis of
COVID-19 from cough sounds. This engine runs on a cloud
server with a front-end programmed as a simple user-friendly
mobile app called AI4COVID-19. The app listens to cough
when prompted, and then sends it to the AI engine wirelessly.
The AI engine first runs a test to see if the recorded sound is
a cough or not a cough. In case the sound is not a cough,
it commands the app to indicate so. The cough detection
part of the AI engine is designed to detect cough even in
the presence of background noise. This is to make the app a
useful screening tool even at public places such as airports and
crowded shopping malls. If a cough is detected, it is passed
on to the diagnosis part of the AI engine. After the AI engine
completes the analysis, the app renders the result with three
possible outcomes:
• COVID-19 likely.
• COVID-19 not likely.
• Test inconclusive.
7) To make the results as reliable as possible with the
limited data available at the moment, we propose and im-
plement a novel architecture for the AI engine. It consists of
three parallel classification solutions designed independently
by three teams. The classifiers outcomes are cross-validated
by an automated mediator. Each classifier has a veto power,
i.e., if all three classifiers do not agree, the app returns ‘Test
inconclusive’. This novel architecture thus minimizes chances
of misdiagnosis, compared to stand alone classifiers with
binary diagnosis.
II. HYPOTHESIS FORMULATION AND DEVISING A
MANAGEABLE VALIDATION STRATEGY GUIDED BY
RELEVANT CLINICAL FINDINGS
Our hypothesis in question is: “Cough sound of the COVID-
19 patients contains unique enough latent features to be used
as a diagnosis medium”. In this section, we describe our
first principle-based approach that established the theoretical
possibility of our hypothesis to be true. Then we describe the
deep domain knowledge-based approach we take to reduce the
amount of data required to test this hypothesis, thereby making
this project feasible in a constrained time.
A. Is COVID-19 cough unique enough to yield AI based
diagnosis?
Unfortunately, cough is a very common symptom of over
a dozen medical conditions caused by either bacterial or viral
respiratory infections not related to COVID-19. Several non-
respiratory conditions can also cause cough. Table I summa-
rizes the non-COVID-19 medical conditions all of which are
known to cause cough. Theoretically, a cough based COVID-
19 diagnosis, therefore, must take into account the cough
sound data associated with all of the conditions listed in the
Table I.
Human ear is definitely not capable to differentiate cough
from all the conditions listed in Table I. If there are no unique
latent features in the cough sound of COVID-19 patients, there
is a risk for a cough-based AI diagnosis tool to confuse cough
caused by any of the diseases identified in Table I with the
cough caused by COVID-19. A brute force-based approach
to evaluate this risk would require gathering cough data from
a large number of patients for each of the conditions listed
in Table I. This deluge of data can be then used to train a
powerful AI engine such as very deep neural network to see if
it can differentiate COVID-19 cough from that caused by all of
other medical conditions listed in Table I. This approach is not
practical at the moment given gathering such all-encompassing
data will take too much time, rendering this approach of no
help for the current pandemic.
To ensure that our developed solution works in practice with
useful accuracy while being trainable with timely available
4Table I: Non-COVID-19 Medical Conditions that can Cause Cough
RESPIRATORY NON-RESPIRATORY
Upper respiratory tract infection
(mostly viral infections) Gastro-esophageal reflux
Lower respiratory tract infection
(pneumonia, bronchitis,
bronchiolitis )
Drugs (angiotensin converting
enzyme inhibitors; beta blockers)
Upper airway cough syndrome Laryngopharyngeal reflux
Pertussis, parapertussis Somatic cough syndrome and ticcough
Tuberculosis Vocal cord dysfunction
Asthma and allergies Obstructive sleep apnea
Early interstitial fibrosis, cystic
fibrosis
Somatic cough syndrome and tic
cough
Chronic obstructive pulmonary
disease (emphysema, chronic
bronchitis)
Smoking
Postnasal drip Foreign body
Croup Mediastinal tumor
Laryngitis Air pollutants
Tracheitis Tracheo-esophageal fistula
Lung abscess Left-ventricular failure
Lung tumor Congestive heart failure
Pleural diseases Psychogenic cough
Interstitial lung disease Idiopathic cough
data, we take another approach that we call domain-aware AI-
design. Domain-aware here refers to the fact that the proposed
AI engine does not solely rely on blind big data churning,
e.g., through a deep neural network. Instead it relies on the
deep domain knowledge of medical researchers trained in
respiratory and infectious diseases to assess and narrow down
the hypothesis testing space, and minimize the amount of data
needed to test our hypothesis.
To this end, the medical researcher in our team began by
analyzing in-depth the pathomorphological changes caused
by COVID-19 in respiratory system by examining the data
reported in numerous recent X-rays [13], [18]–[20] and CT-
scans based studies [14], [21], [22] of COVID-19 patients.
The goal here is to see if the pathomorphological alterations
caused by COVID-19 are distinct from that of other common
medical conditions, particularly the ones identified in Table I,
that are well known to cause cough. If this turns out to be
the case, then in cough caused by COVID-19 we should have
latent features distinct from the cough caused by the other
medical conditions. An appropriately designed AI should then
be able to pick these cough feature idiosyncratic to COVID-19
infection and yield a reliable diagnosis, given enough labeled
data. If no such differences exist at pathomorphological level,
the idea of cough based COVID-19 diagnosis should be
dropped. Because in that case, any AI based diagnosis yielded
from cough is more likely to be frivolous correlation and not a
meaningful causal relationship. Such-AI based diagnosis will
be an artifact of the training data rather than unique latent
features of COVID-19 caused cough. Such domain oblivious
solution irrespective of its performance in lab, will not be
useful in practice.
B. Distinct Pathomorphological Alternations in Respiratory
System Caused by COVID-19
Recent studies show that in COVID-19 infected people,
there are distinct early pulmonary pathological signs even
before the onset of the symptoms of COVID-19 such as
dry cough, fever and some difficulty in breathing [23]. Early
histological changes include evident alveolar damage with
alveolar edema and proteinaceous exudates in alveolar spaces,
with granules; inflammatory clusters with fibrinoid material
and multinucleated giant cells; vascular congestion. Reactive
alveolar epithelial hyperplasia and fibroblastic proliferation
(fibroblast plugs) was indicative of early organization [23].
CT scan based studies shows that on the early stage of
COVID-19 disease, it mainly manifests as inflammatory in-
filtration restricted to the subpleural or peribronchovascular
regions of one lung or both lungs, exhibiting patchy or
segmental pure ground-glass opacities (GGOs) with vascular
dilation. There is an increasing range of pure GGOs and
involvement of multiple lobes of lung, consolidation of lesions
and crazy-paving patterns during the progressive stage. There
are diffuse exudative lesions and lung “white-out" during
advanced stage [24].
In some patients, COVID-19 leads to onset of pneumonia
and pneumonia is marked by a peculiar cough. However,
pneumonia can also be caused by many other factors includ-
ing non-COVID-19 viral or bacterial infections. Therefore,
the question arises: is there a difference between COVID-
19 caused pneumonia and other types of pneumonia that
can be expected to translate into a difference in associated
cough’s latent features? Researches show that compared to
non-COVID-19 related pneumonia, COVID-19 related pneu-
monia on chest CT scan was more likely to have a peripheral
distribution (80% vs. 57%), ground-glass opacity (91% vs.
68%), vascular thickening (59% vs. 22%), reverse halo sign
(11% vs. 9%) and less likely to have a central+peripheral
distribution (14% vs. 35%), air bronchogram (14% vs. 23%),
pleural thickening (15% vs. 33%), pleural effusion (4% vs.
39%) and lymphadenopathy (2.7% vs. 10.2%) [25].
These findings suggest that cough sound signatures with
COVID-19 caused pneumonia are likely to have some idiosyn-
crasies stemming from the distinct underlying pathomorpho-
logical alterations.
Furthermore, AI based analyses of X-ray [13] and CT
scan [14] of the respiratory system have also shown to exploit
the differences in pathomorphological alternations caused by
COVID-19 to perform differential diagnosis among bacterial
infection, non-COVID-19 viral infection and COVID-19 viral
infection, with remarkable accuracy. This further implies that
COVID-19 affects the respiratory system in a fairly distinct
way compared to other respiratory infections. Therefore, it is
logical to hypothesize that the sound waves of cough produced
by COVID-19 infected respiratory system is also likely to have
unique latent features and the risk of these features overlapping
with those associated with other respiratory infections is low.
This hypothesis is supported not only by our own prior studies
for diagnosing several common respiratory diseases using
cough [15], but also in a recent clinically validated and widely
5publicized study [26]. In [26], a large team of researchers
showed that cough alone can be used to diagnose asthma,
pneumonia, bronchiolitis, croup, and lower respiratory tract
infections with over 80% sensitivity and specificity. Another
very recent study shows that cough can be used to successfully
diagnose influenza [27].
However, to the best of authors’ knowledge, no study so
far has leveraged cough for diagnosis of COVID-19 while
presenting a mobile app base solution for anytime, anywhere
virtual testing and pre-screening for COVID-19.
III. DATA DESCRIPTION AND PRACTICAL VIABILITY OF
THE SOLUTION WITH AVAILABLE DATA
As mentioned earlier, ideally cough data associated with
all diseases listed in Table I is desirable for such a project.
However, gathering such mammoth data is not possible in this
time constrained project, as COVID-19 pandemic needs rapid
response. To achieve meaningful results in the constrained
time, we leverage domain knowledge, instead of just seeking
big data. From Table I, using the insights from Section II,
we shortlist cough causing infections that are most likely to
confuse our AI engine due to having similar pathomorpholog-
ical changes in the respiratory system as of COVID-19 and,
hence, similar cough signatures. The shortlist includes pertus-
sis, bronchitis, asthma, pneumonia, bronchiolitis, croup, and
influenza. We further note that prior studies have shown that
cough associated with all of these seven medical conditions,
except pertussis and bronchitis [26], [27], have unique latent
features. We use findings from these earlier studies to reduce
the scope of our data gathering campaign and differential
analysis to only the respiratory diseases, the cough for which
has not been analyzed before for having unique features, i.e.,
pertussis and bronchitis.
A. Data used for training cough detector
In order to make AI4COVID-19 app employable in a public
place or where various background noises may exist (e.g.,
airport), we design and include a cough detector in our AI-
Engine. This cough detector acts as a filter before the diagnosis
engine and is capable to distinguish sound from 50 other
common environmental noise. To train and test this detector,
we use ESC-50 dataset [28]. The ESC-50 dataset is a publicly
available dataset that provides a huge collection of speech and
environmental sounds. This collection of sounds is categorized
into 50 classes, one of these being cough sounds. We have used
993 cough sounds and 993 non-cough environmental sounds
for training of our cough detection system.
B. Data used for training COVID-19 diagnosis engine
To train our cough diagnosis system, we collected cough
sounds from COVID-19 patients as well as pertussis and bron-
chitis. We also collected normal coughs, i.e., cough sounds
from healthy people. At the time of writing, we had access to
102 bronchitis, 131 pertussis, 48 COVID-19, and 76 normal
cough sounds to train and test our diagnosis system. Obviously
these are very small numbers of samples and more data is
Figure 1: Visualization of features for the four classes via t-SNE (gray triangles
correspond to normal, blue circles correspond to bronchitis, black stars correspond to
pertussis, and orange diamonds represent COVID-19 cough.
needed to make the solution more reliable. New COVID-19
cough samples are arriving daily and we are using these unseen
samples to test the trained algorithm. Even with small training
data, very promising accuracy has been observed on unseen
test samples, as reported in Section V.
C. Data pre-processing and visualization to evaluate practical
feasibility of AI4COVID-19
In Section II, we assessed and established the theoretical
viability of our hypothesis using deep domain knowledge.
However, in machine learning based solutions, theoretical
viability does not guarantee practical viability as the end
outcome depends on the quantity and quality of the data, in
addition to the sophistication of machine learning algorithm
used. Therefore, here we use the available cough data from
the four classes to first evaluate the practical feasibility of a
cough based COVID-19 diagnosis solution.
We convert the cough data for all four classes into Mel scale
for further processing. The Mel scale is a pitch categorization
where listeners judge changes in pitch to be equal in distance
from one another along this scale. It is meant to make changes
in frequency, such as with a spectrogram, more closely reflect
audible changes. There are several methods for converting the
frequency scale to Mel. Here, we convert frequency f into Mel
scale m as:
m = 2595 × log10
(
1 +
f
700
)
(1)
We perform Cepstral analysis on the Mel spectrum of
audio cough samples to compute their Cepstral coefficients,
commonly known as Mel Frequency Cepstral Coefficients
(MFCC). The extracted MFCC features for every sample result
in an M ×N matrix, where each column represents one signal
frame and each row represents extracted MFCC features for
a specific frame. The number of frames N can vary from
sample to sample. There are several possible ways to use
these extracted features for classification. In our approach,
we extract two M × 1 MFCC based feature vectors for each
input cough sample and concatenate them into a single final
2M × 1 feature vector for that sample. For the first feature
vector, we take the mean of MFCC features corresponding
to all the frames. For the second feature vector, we take the
top few Principle Component Analysis (PCA) projections of
6Figure 2: Proposed system architecture of AI4COVID-19, showing snapshot of Smartphone App at user front-end and back-end cloud AI-engine blocks consisting of Cough Detector
block (further elaborated in Figure 3) and COVID-19 diagnosis block containing Deep Learning-based Multi-Class classifier (DL-MC), Classical Machine Learning-based Multi-Class
classifier (CML-MC), and Deep Learning-based Binary-Class classifier (DL-BC), further elaborated in Figure 4 and Figure 5.
the MFCC features across all the frames and combine them
into a single M × 1 vector by taking their magnitude. Finally,
we concatenate both feature vectors into a single 2M × 1
feature vector. This approach is further illustrated in Figure 5
in Section IV-C.
Figure 1 illustrates the 2-D visualization of these features
for the four classes through t-distributed Stochastic Neigh-
bor Embedding (t-SNE) with classification decision bound-
aries/contours. It can be seen from the figure that different
cough types possess features distinct from each other, and
the features for COVID-19 are different from other cough
types, such as bronchitis and pertussis. Hence, this observation
validates the practical viability of AI4COVID-19 based diag-
nosis encouraging us to proceed towards AI-engine design for
maximum accuracy and efficient implementation.
IV. THE AI4COVID-19 AI-ENGINE
In this section we explain the system architecture and
the details of a two stage solution that we developed for:
1) detection of cough sound from mixed cough, non-cough,
and noisy sounds; and 2) diagnosis of COVID-19 from the
cough sound.
A. System Architecture
The overall system architecture is illustrated in Figure 2.
The smartphone app records sound/cough when prompted
with the press and release button. The recorded sounds are
transmitted to the server when the diagnosis button is pressed.
At the server, the sounds are first fed into the cough detector.
In case, the sound is not detected to be cough, the server
commands the app to prompt so. In case, the sound is
detected to be a cough, the sound is forwarded to the three
parallel, independent classifier systems: Deep Learning-based
Multi Class classifier (DL-MC), Classical Machine Learning-
based Multi Class classifier (CML-MC), Deep Learning-based
Binary Class classifier (DL-BC). The results of the all three
classifiers are then passed on to a mediator. The app reports
a diagnosis only if all three independent classifiers return
identical classification results. If the classifiers do not agree,
the app returns ‘test inconclusive’. This tri-pronged mediator
centered novel architecture is designed to effectively minimize
the probability of misdiagnosis. With this architecture, results
show that AI4COVID-19 engine predicting ‘COVID-19 likely’
when the subject is not suffering from COVID-19 or vice-versa
is extremely low, almost zero on the testing data available at
the time of writing. This idea is inspired from the "second
opinion" practice in health care. The added caution here is that
three independent opinions (diagnosis) are solicited, each with
veto power. How this novel architecture manages to reduce
the overall misdiagnosis rate of the AI4COVID-19 despite the
relatively higher misdiagnoses rate of individual classifiers is
further explained in Section V-C through (9) and (10).
The details of detection and diagnosis classifiers are pre-
sented below.
B. Cough Detection
The recorded cough sample is forwarded to our network
server where the cough detector engine first computes its Mel-
spectrogram (as explained in Section III-C), converts it into
grayscale to unify the intensity scaling and reduce the image
dimensions, and feed it into the Convolutional Neural Network
(CNN) to decide whether the recorded sound is of cough or
not.
An overview of our used CNN structure is shown in
Figure 3. As the input Mel spectrogram image is of high di-
mensions, it’s first passed through a 2×2 max-pooling layer to
reduce the overall model complexity before proceeding. This
relatively smaller image is then passed to two convolutional
layers consisting of 32 filters and 5 × 5 kernel size with a
max-pooling layer in between to learn the complex features,
which are then passed to a 2× 2 max-pooling to represent the
learned features in lower dimensions. The image is flattened
to 1 dimension and then passed to two fully connected layers
with 128 neurons each. 0.5 dropout is used in both of these
to avoid overfitting.
The final layer is the softmax classification layer with 2
neurons to distinguish between cough and not cough for the
given input. The number of convolutional and fully connected
layers are kept low to minimize potential overfitting issues.
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Figure 3: Cough detection classifier.
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Figure 4: Deep Learning-based Multi-Class classifier (DL-MC).
Since ReLU is the current standard for CNNs, it is used for
the activation functions of this model, while Adam [29] is
used as the optimizer due to its relatively better efficiency and
flexibility. A binary cross entropy loss function completes the
detection model.
C. COVID-19 Diagnosis
In the case of cough detection, the cough sound is forwarded
to our tri-pronged mediator-centered AI engine to diagnose
between COVID-19 and non-COVID-19 coughs. In order to
produce results with maximum reliability, with the limited data
available at the moment, the three classifiers used in the sys-
tem use different approaches and are designed independently
by three teams and cross-validated. The three classification
approaches are described below.
1) Deep Learning-based Multi Class classifier (DL-MC):
The first solution leverages a CNN based four class classifiers
using Mel spectrograms (described above) as input. The four
classes here are cough caused by: 1) COVID-19, 2) pertussis,
3) bronchitis, or 4) normal person with no known infection.
The same type of machine learning categorization procedure
used for binary-class cough detection is applied to the labeled
cough data originating from several different illnesses. How-
ever, due to the differences between two coughs of differing
illnesses typically being subtler than a cough and non-cough
event, a more complex set of layering is required for this
version of the CNN. This classifier architecture is illustrated in
Figure 4. The diagnosis CNN begins with a 2×2 max-pooling
layer which is followed by two blocks of layers, each block
comprising two convolutional layers followed by a 2 × 2 max
pooling layer and a 0.15 dropout. All the convolutional layers
have 16 filters and a 3 × 2 kernel size. The complex learned
features from these 4 convolutional layers are flattened and
then passed to a fully connected layer of 256 neurons followed
MFCC
(M x N)
Mean MFCC
(M x 1)
Top P (M x 1)
PCA projections
(M x P)
Concatenate
(2M x 1)
Class balancing
Cough
audio
Magnitude of 
(M x 1)
each row
Normalization using
standard scalar
SVM training and
parameter optimization
Figure 5: Classical Machine Learning-based Multi-Class classifier (CML-MC).
by a 0.15 dropout layer to prevent overfitting. Finally, the
output layer with 4 neurons and softmax activation function
is used to classify the input between 4 possible diseases.
2) Classical Machine Learning-based Multi Class classifier
(CML-MC): A second parallel diagnosis test uses classic
machine learning instead of deep learning. It begins with a
different pre-processing of cough sounds. Instead of using
spectrogram like the first classifier, it uses MFCC and PCA
based feature extraction as explained in Section III-C. These
smart features are then fed into a multi-class support vector
machine for classification.
Class balance is achieved by sampling from each class
randomly such that the number of samples equals to the
number of minority class samples, i.e., class with the lowest
number of samples. Using the concatenated feature matrix (of
mean MFCC and top few PCAs) as input, we perform SVM
with k-fold validation for 100,000 iterations. This approach is
illustrated in Figure 5.
3) Deep Learning-based Binary Class classifier (DL-BC):
The third parallel diagnosis test also uses deep learning based
CNN on the Mel spectrogram image of the input cough
samples, similar to the first branch of the AI engine, but
performs only binary classification of the same input, i.e., is
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Figure 6: Normalized confusion matrix for cough detection (in percentage).
Table II: Performance Metrics for Cough Detection
F1-Score
(%)
Sensitivity
(%)
Specificity
(%)
Precision
(%)
Accuracy
(%)
97.92 98.58 97.24 97.28 97.91
the cough associated COVID-19 or not. The CNN structure
used for this technique is the same as the one used for cough
detector, elaborated in Figure 3.
V. RESULTS AND DISCUSSION
In order to evaluate the model we use the performance
metrics of accuracy, specificity, sensitivity/recall, precision,
F1-score on validation set and also cross-validate the models.
These metrics are calculated as follows:
accuracy =
TP + TN
TP + TN + FP + FN
(2)
specificity =
TN
TN + FP
(3)
sensitivity/recall =
TP
TP + FN
(4)
precision =
TP
TP + FP
(5)
F1-score = 2 ∗
(
precision × recall
precision + recall
)
(6)
Here, TP,TN, FP, and FN refer to True Positives, True
Negatives, False Positives, and False Negatives, respectively.
These performance metrics are based on mean confusion
matrices from 2-fold cross validation.
A. Cough Detection
The confusion matrix and performance metrics for detection
algorithm are reported in Figure 6 and Table II, respectively.
Results demonstrate that our cough detection algorithm can
classify between cough event and no cough event with an
overall accuracy of 97.91%.
Table III: Performance Metrics for DL-MC
F1-
Score
(%)
Sensitivity
(%)
Specificity
(%)
Precision
(%)
Accuracy
(%)
Overall - - - - 93.56
COVID-19 93.14 99.67 97.50 87.42 -
Pertussis 94.74 90.00 100.0 100.0 -
Bronchitis 90.32 93.33 93.74 87.50 -
Normal 99.77 100.0 99.95 99.54 -
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100 0 0 0
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Figure 7: Normalized confusion matrix for cough diagnosis (in percentage).
B. COVID-19 Diagnosis
The performance metrics for the fi st classifier, DL-MC
classifier are reported in Table III. At the moment, with limited
data available, the overall accuracy of deep learning based
multi-class classifier is 93.56%. Future work will continue to
improve this model as more training data becomes available
for CNN.
For the second classifier, i.e., CML-MC classifier, the nor-
malized confidence matrix is shown in Figure 7 and the CDF
of overall accuracy with varying k’s in k-fold cross validation
is shown in Figure 8. Table IV reports the performance metrics
for this approach, utilizing data available at this moment.
Results indicate an overall accuracy of 94.06%.
Performance metrics for the third approach, DL-BC are
reported in Table V. Currently, the classification accuracy with
this approach is 88.89%. The lower classification accuracy of
this classifier can be attributed to class bias, since the number
of non-COVID cough samples are much larger than COVID-
19 cough samples, when binary classification is chosen. This
artifact is likely to diminish once more data becomes available.
While at the moment, the performance of the two deep
learning based classifiers (DL-MC and DL-BC) is slightly
Table IV: Performance Metrics for CML-MC
F1-
Score
(%)
Sensitivity
(%)
Specificity
(%)
Precision
(%)
Accuracy
(%)
Overall - - - - 94.06
COVID-19 97.99 96.76 99.76 99.27 -
Pertussis 89.12 85.33 97.94 93.26 -
Bronchitis 90.45 94.13 95.33 87.04 -
Normal 98.58 100.0 99.04 97.19 -
9Table V: Performance Metrics for DL-BC
F1-Score
(%)
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Specificity
(%)
Precision
(%)
Accuracy
(%)
90.32 93.33 83.33 87.50 88.89
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Figure 8: Overall accuracy CDF for varying k-fold experiments in classical ML
approach.
lower than the manual feature extraction based classic machine
learning classifier (CML-MC), as the data becomes abundant,
the deep learning based classifiers are likely to yield better
performance. This is expected, because with large amount
of training data automatic feature extraction capability of the
deep neural network is expected to extract even more subtle
distinct features hidden in the data than the manual feature
extraction used in the second classifier, i.e., CML-MC.
C. Overall Performance of AI4COVID-19 AI Engine
After looking at the performance of the three different
independent classifiers used in our architecture, we now ana-
lyze the overall performance of AI4COVID-19 AI engine that
utilizes a mediator based novel architecture. Let k1, k2, k3
be the predicted class labels for the three classifiers, DL-MC,
CML-MC and DL-BC, respectively and k f be the predicted
diagnosis result of the app. The possible values that k f can
take are ‘COVID-19 likely’ (C), ‘COVID-19 not likely’ (C ′ )
and ‘test inconclusive’ (I).
Then, the probability that the app predicts ’COVID-19
likely’, when the patient actually has COVID-19, can be
calculated as:
P(k f = C |C) = P(k1 = C |C) · P(k2 = C |C) · P(k3 = C |C)
= 0.99 · 0.97 · 0.93 = 0.893 (7)
The probability that the app predicts ‘COVID not likely’
when the subject actually does not have COVID-19 can be
represented as:
P(k f = C ′ |C ′) = P(k1 = C ′ |C ′) · P(k2 = C ′ |C ′) · P(k3 = C ′ |C ′)
= 0.975 · 0.997 · 0.833 = 0.809 (8)
The app can also predict ‘COVID-19 likely’ when the
subject is not suffering from COVID-19 or vice-versa. In these
cases, we can write the probabilities as:
P(k f = C |C ′) = P(k1 = C |C ′) · P(k2 = C |C ′) · P(k3 = C |C ′)
= 0.025 · 0.002 · 0.167 = 0.0000084 (9)
P(k f = C ′ |C) = P(k1 = C ′ |C) · P(k2 = C ′ |C) · P(k3 = C ′ |C)
= 0.003 · 0.032 · 0.067 = 0.00000643 (10)
Equations (9) and (10) signify the importance of the me-
diator in our system architecture and show how this novel
architecture is able to reduce the overall misdiagnosis rate
of AI4COVID-19. From (9), the probability that the app will
predict ‘COVID-19 likely’ when the subject is not suffering
from COVID-19 is near zero owing to the near zero false
positive rate of CML-MC classifier. Conversely, probability
that app will predict ‘COVID-19 not likely’ when the subject
is actually suffering from COVID-19 is almost zero owing to
the almost zero false negative rate of DL-MC classifier. Hence,
the mediator in AI4COVID-19 architecture complements the
weakness of one classifier with the strength of other and vice
versa, resulting in reduced misdiagnosis rate as compared to
using these classifiers independently, i.e., without the proposed
mediator.
In the cases where app reports ‘test inconclusive’, the person
can either have COVID-19 or not, in reality. The respective
probabilities for those cases are:
P(k f = I |C) = 1 − [P(k f = C |C) + P(k f = C ′ |C)]
1 − [0.893 + 0.00000643] = 0.107 (11)
P(k f = I |C ′) = 1 − [P(k f = C |C ′) + P(k f = C ′ |C ′)]
1 − [0.0000084 + 0.809] = 0.191 (12)
Currently, the app would predict an inconclusive test result
29.8% of the time (P(k f = I) = P(k f = I |C) + P(k f = I |C ′)).
This percentage can be reduced by switching to a mediation
scheme where app result reflects simple or weighted majority
of the N number of classifiers. However, to keep the misdi-
agnosis rate close to zero, this scheme will be explored once
more data becomes available. The results are summarized in
Table VI.
VI. POTENTIAL UTILITIES OF THE AI4COVID-19
The AI4COVID-19 app based preliminary diagnosis is not
meant to replace or compete with the medical grade testing by
any means. Instead, the proposed solution offers the following
complementing use cases to control the pandemic.
1) Enabling tele-screening for anyone, anywhere, anytime.
2) Addressing the shortage of testing facilities.
3) Opportunity to protect medics from unnecessary expo-
sure, particularly for non-critical patients where the medical
advice for whom anyway would be “stay at home” or “self-
isolate” to wait for self-healing.
10
Table VI: The Overall Current Performance of AI4COVID-19 AI Engine
Event Probability
App reports ‘COVID-19 likely’ when the subject actually has COVID-19 0.893
App reports ‘COVID-19 likely’ when the subject actually does not have COVID-19 0.0000084
App reports ‘COVID-19 not likely’ when the subject actually does not have COVID-19 0.809
App reports ‘COVID-19 not likely’ when the subject actually has COVID-19 0.00000643
App reports ‘test inconclusive’ when the subject actually has COVID-19 0.107
App reports ‘test inconclusive’ when the subject actually does not have COVID-19 0.191
4) Minimizing covert spread that happens to be the biggest
problem at this stage of pandemic.
5) Tracing and monitoring the spread. This is particularly
easy with AI4COVID-19 as the cough samples can be spatio-
temporally tagged anonymously, without having to compro-
mise the patient’s privacy.
6) AI4COVID-19 can be used as a low cost screening tool,
instead of or in addition to the temperature scanner at the
airports, borders or elsewhere as needed. This is possible
because our tests show that the app can diagnose COVID-
19 even in a non-spontaneous cough of COVID-19 positive
people.
7) The app can help in enabling and maintaining informed
social distancing and self-isolation.
8) By default the app can provide centralized record of tests
with spatial and temporal stamps. Thus, the data gathered from
the app can be used for long term planning of medical care
and policy making.
VII. KEY LIMITATIONS OF CURRENT VERSION OF
AI4COVID-19
At the time of writing, the performance of AI4COVID-19
app is limited by the following factors:
1) The quantity of the training and testing data. Due to
time constraints and difficulty of getting cough data, we could
gather data only from a small number of patients for each
of the four groups. We tried to minimize the impact of this
limitation by developing a novel architecture that combines
data hungry approaches that are capable to extract more
hidden features i.e., deep learning, with the ML approaches
that can work with a small amount of data through manual
feature extraction. Still, the need for more data cannot be
overemphasized.
2) The quality of the training and testing data: We have
strived to ensure that the data is correctly labeled. However,
any error in the labeling of the data that managed to slip
through our scrutiny, is likely to impact reported performance.
Such impact can be particularly pronounced when the data is
not that big in the first place.
3) Our in-depth medical differential analysis suggested
that COVID-19 associated pathomorphological alternations are
fairly distinct and hence cough of COVID-19 patients is likely
to have at least some distinct latent features. However, this
does not guarantee the absence of overlap in COVID-19 cough
features and those of diseases not included in the training and
testing. The approach we used to combat this issue is the
clever mediator based architecture that practically eliminates
misdiagnosis by declaring test to be inconclusive if the cough
samples are even slightly confusing. Still, we are working
to address this limitation in future releases of AI4COVID-19
by incorporating cough associated with other non-COVID-19
medical conditions identified in Table I.
4) Randomized clinical trial-based validation: In the end,
the only way to reliably evaluate the performance of the
proposed AI4COVID-19 based testing is a controlled clinical
trial. The findings of this paper provide promising enough pre-
liminary results and proof of concept to encourage such trials
and systematic large-scale cough data gathering campaigns.
VIII. CONCLUSION
Scarcity, cost and long turnaround time of clinical testing
are key factors behind covert rapid spread of the COVID-19
pandemic. Motivated by the urgent need, this paper presents
a ubiquitously deployable AI-based preliminary diagnosis tool
for COVID-19 using cough sound via a mobile app. The core
idea of the tool is inspired by our prior studies which show
that cough can be used as a test medium for diagnosis of a
variety of respiratory diseases using AI. To see if this idea
is extendable to COVID-19, we perform in-depth differential
analysis of the pathomorphological alternations caused by
COVID-19 relative to other cough causing medical conditions.
We note that the way COVID-19 affects the respiratory system
is substantially unique and hence cough associated with it is
likely to have unique latent features as well. We validate the
idea further by the visualization of latent features in cough
of COVID-19 patients and two common infections, pertussis
and bronchitis as well as non-infectious coughs, all of which
sound the same to a human ear. Building on the insights from
the medical domain knowledge, we propose and develop a
novel tri-pronged mediator centered AI-engine for cough based
diagnosis for COVID-19, named AI4COVID-19. The results
show that the AI4COVID-19 app is able to perform diagnosis
of COVID-19 with negligible misdiagnosis probability, thanks
to its novel risk-avert architecture.
Despite its impressive performance, AI4COVID-19 is not
meant to compete with clinical testing. Instead, it offers a
unique functional tool to timely, cost-effectively and most
importantly safely monitor, trace, track and thus control the
rampant spread of the global pandemic by virtually enabling
testing for everyone. While we are working on improving
the AI4COVID-19, this paper is meant to present a proof of
concept to encourage clinical trial and community support for
more labeled data. Our hope is that AI4COVID-19 app can be
leveraged to pre-screen for COVID-19 at a population scale.
The AI4COVID-19 enabled tele-screening can alleviate the
current crushing burden on the overwhelmed medical systems
around the world and thus can help save countless lives.
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